Enterococcus faecalis

Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023

Retrieved on: 
Tuesday, October 17, 2023
Efficacy, Staphylococcus, Methicillin-resistant Staphylococcus aureus, Ambrose, Abstract, Treatment, Clinical, Circulatory system, MRSA, Biomedical Advanced Research and Development Authority, BARDA, Enterococcus faecalis, Infection, ASPR, MSSA, IDSA, Isolates, Laboratory, Liolios Xirolivaditis, Staphylococcus aureus, PK/PD models, SAB, ABSSSI, CABP, Bronchopneumonia, Administration for Strategic Preparedness and Response, Streptococcus pneumoniae, Prescription Drug User Fee Act, Duke University School of Medicine, Infectious Diseases Society of America, Randomness, Development, Administration, Safety, Patient, PDUFA, HHS, Pharmaceutical industry, Vaccine, Ceftobiprole, Litherland, Enterococcus, Allschwil, Streptococcus, Bloodstream infections

Dr. Marc Engelhardt, Chief Medical Officer of Basilea, stated: “The data presented at IDWeek provide further evidence for the potent antimicrobial activity of ceftobiprole against MRSA and other clinically relevant pathogens.

Key Points: 
  • Dr. Marc Engelhardt, Chief Medical Officer of Basilea, stated: “The data presented at IDWeek provide further evidence for the potent antimicrobial activity of ceftobiprole against MRSA and other clinically relevant pathogens.
  • It also provides results of pharmacokinetic-pharmacodynamic modeling supporting the dosing regimens to treat severe bacterial infections from the successful clinical phase 3 studies.
  • Abstract #1946 – In Vitro Activity of Ceftobiprole against Staphylococcus aureus Bacteremia Isolates from the United States (2018–2020) – L. Duncan, M. Castanheira, J. I.
  • Smart, M. E. Jones, P. G. Ambrose, K. Litherland
    Abstract #2561 – Population Pharmacokinetic Analyses for Ceftobiprole Using Data from Phase 1 and 3 Studies – A. P. Cammarata, K. Litherland, M. C. Safir, S. M. Bhavnani, M. Saulay, J. I.

Sani Sport machine becomes focal point of Cornell Covid-19 Study

Retrieved on: 
Tuesday, January 24, 2023
Ozone, Escherichia coli, PPE, Half-life, Houston, Sterilization, Catheter, Enterococcus faecalis, Syringe, Disinfectant, Bacteria, Escherichia, Risk, Infection, Virus, Weill Cornell Medicine, Medical device, Sewage treatment, Gene, Deinococcus

MONTREAL, Jan. 24, 2023 /PRNewswire/ - It is an absolute honor for Sani Sport to be a part of this medical study , which has now been formally published in Genes.

Key Points: 
  • MONTREAL, Jan. 24, 2023 /PRNewswire/ - It is an absolute honor for Sani Sport to be a part of this medical study , which has now been formally published in Genes.
  • As the pandemic came to a rise, the Weill Cornell Medical College sought out a solution on how to reduce bacteria and viruses within a wide range of medical equipment.
  • The Sani Sport Supreme machine quickly became the focal point of their study.
  • The Sani Sport Supreme is used throughout law enforcement, the military and professional sports to significantly reduce pathogens in their protective equipment.

VIRINX Announces the Successful Contactless Suppression of Wound-Infecting Bacteria by its Viper22 System

Retrieved on: 
Tuesday, October 18, 2022
IOT, Prevalence, Wound healing, Staphylococcus, Diagnosis, Infection, Methicillin-resistant Staphylococcus aureus, Candida albicans, Streptococcus pyogenes, Escherichia coli, Multimedia, Risk, Hertz, Company, Acinetobacter baumannii, Spore, CEO, Statista, Patent, Abscess, Bacteria, Enterococcus faecalis, Pseudomonas aeruginosa, Osteomyelitis, View, Pharmaceutical industry, Mobile phone

LAKE FOREST, Calif., Oct. 18, 2022 /PRNewswire/ -- Virinx LLC ("VIRINX" or "the Company"), a developer of highly integrated IoT devices, announced the successful preliminary test results of its Viper22 system, which is a miniature noncontact wound and fungus infection treatment system.

Key Points: 
  • LAKE FOREST, Calif., Oct. 18, 2022 /PRNewswire/ -- Virinx LLC ("VIRINX" or "the Company"), a developer of highly integrated IoT devices, announced the successful preliminary test results of its Viper22 system, which is a miniature noncontact wound and fungus infection treatment system.
  • Appropriate antimicrobial therapy is the cornerstone of successful wound treatment.
  • "VIRINX has previously evaluated the impact of using microwave frequencies of 6 to 10 GHz and exposing bacteria to these microwave frequencies on glass surfaces for few minutes.
  • The bacteria counts were reduced by more than three 10log on glass surfaces," stated Dr. Fred Mohamadi, VIRINX's CEO.

Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022

Retrieved on: 
Wednesday, July 20, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MRSA, Patient, Streptococcus agalactiae, MSSA, Streptococcus anginosus group, Bacteria, Food and Drug Administration, Tablet, Culture, Drug of last resort, Marketing, Pyelonephritis, ABSSSI, Review, Staphylococcus aureus, Infection, Streptococcus constellatus, Diarrhea, U.S. Securities and Exchange Commission, Human, Union, Research, Enterococcus, Merck, Moxifloxacin, Streptococcus intermedius, Private Securities Litigation Reform Act, Urinary tract infection, GLOBE, Streptococcus anginosus, Food, COVID-19, Conference, Nausea, Streptococcus pyogenes, Vomiting, Cutis laxa, Linezolid, Fosfomycin, Enterococcus faecalis, Bronchopneumonia, Complicated, Therapy, NASDAQ, Gram, Cystic fibrosis, Pharmaceutical industry, Streptococcus

ET to discuss the financial results and recent corporate highlights.

Key Points: 
  • ET to discuss the financial results and recent corporate highlights.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
  • However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Top International Academic Institutions Complete Independent Studies Validating C-POLAR™ Technology

Retrieved on: 
Tuesday, July 5, 2022
Transport, Czech Academy of Sciences, COVID 19, Staphylococcus aureus, Pseudomonas aeruginosa, Tampere University, Harvard Medical School, COVID, S. aureus, Enterococcus faecalis, Peckham Technology Inc, University, Arrest, GLOBE, Infection, COVID-19, Open University of Hong Kong, Coronavirus, Virus inactivation, Kidney, Overalls, Massachusetts General Hospital, Metropolitan University, Hospital, ASHRAE, Technology, Health, Virus, Solution, Motivation, Escherichia coli, Safety, Czech Republic, Severe acute respiratory syndrome coronavirus 2, Society, University of Minnesota, Vaccine, Pharmaceutical industry, Pseudomonas, Science

The independent studies found that the C-POLAR material was able to eradicate more than 99.9% of pathogens within 5 minutes and is safe for human applications.

Key Points: 
  • The independent studies found that the C-POLAR material was able to eradicate more than 99.9% of pathogens within 5 minutes and is safe for human applications.
  • C-POLAR Technologies is committed to revolutionizing the bioprotection industry with technology that is rooted in significant, validated science, said Steve Gorlin, Chairman of C-POLAR Technologies, Inc.
  • The study found that C-POLAR treated material significantly reduced pathogens viability, with up to 92% reduction in certain pathogens.
  • The companys proprietary technology, C-POLAR material is highly effective and efficient where multiple international studies have shown its ability to arrest, inactivate and eradicate up to 99.9% of viruses and microorganisms.

Nabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the End of 2026

Retrieved on: 
Thursday, May 5, 2022
MSD, Enterococcus, Drug of last resort, Culture, Neutropenia, NASDAQ, GLOBE, Enterococcus faecalis, MSSA, Streptococcus anginosus group, Merck, Food, Gram, Streptococcus agalactiae, Safety, ABSSSI, CDC, Patient, Streptococcus anginosus, Infection, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Staphylococcus aureus, Streptococcus pyogenes, MRSA, Marketing, Streptococcus intermedius, Streptococcus constellatus, Growth, Pharmaceutical industry, Vaccine, Streptococcus

Nabriva has been marketing and distributing SIVEXTRO in the United States and certain of its territories as part of an exclusive agreement executed in July 2020 with Merck.

Key Points: 
  • Nabriva has been marketing and distributing SIVEXTRO in the United States and certain of its territories as part of an exclusive agreement executed in July 2020 with Merck.
  • The term of the agreement can be further extended by an additional three-year period, subject to mutual agreement.
  • Ted Schroeder, Chief Executive Officer of Nabriva, commented, We are excited to announce the extension of our agreement with Merck to promote and distribute SIVEXTRO for at least an additional three years.
  • This is a testament to our successful and collaborative relationship with Merck, and our strong commercial performance with SIVEXTRO.

OpGen Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of Clinical Microbiology

Retrieved on: 
Thursday, February 10, 2022
Adoption, Nadine Opgen-Rhein, U.S. Securities and Exchange Commission, Drug Quality and Security Act, Private Securities Litigation Reform Act, Goal, Precision medicine, Technology, Public health, Gene, COVID-19, Gram-negative bacteria, Whole genome sequencing, AST, Aminoglycoside, Drug resistance, Journal, Beta-lactam, Enterococcus faecalis, Lancet, NGS, PPA, Infection, Securities Act of 1933, Culture, Antibiotic sensitivity testing, Infectious Diseases Society of America, WGS, Drug of last resort, Nasdaq, Pseudomonas aeruginosa, Detection, GLOBE, European Journal of Clinical Microbiology & Infectious Diseases, Bacteria, AMR, NPA, Informatics, Colistin, Solution, Security (finance), Securities Exchange Act of 1934, Fatality, FDA, Hospital, IDSA, Vaccine, MD, Enterobacterales

The Acuitas AMR Gene Panel results were compared with a combined reference standard including whole genome sequencing (WGS), organism identification and phenotypic antimicrobial susceptibility testing using standard of care microbiology culture.

Key Points: 
  • The Acuitas AMR Gene Panel results were compared with a combined reference standard including whole genome sequencing (WGS), organism identification and phenotypic antimicrobial susceptibility testing using standard of care microbiology culture.
  • In this publication titled Multicenter Evaluation of the Acuitas AMR Gene Panel for Detection of an Extended Panel of Antimicrobial Resistance Genes among Bacterial Isolates 1, the authors note that associating the AMR markers with not susceptible phenotypic results is a key differentiator of the FDA-cleared Acuitas AMR Gene Panel compared to other molecular panels that simply detect the presence or absence of a gene.
  • Several clinical cases illustrating the potential utility of the Acuitas AMR Gene Panel were presented during a recent webinar titled Discovering the FDA-cleared Acuitas AMR Gene Panel: Building a Case for Clinical Utility .
  • This press release includes statements regarding the publication of results of a recent study of the Acuitas AMR Gene Panel.

MALACHITE INNOVATIONS ANNOUNCES TWO GRANTED U.S. PATENTS AND NEW PCT PATENT FILING

Retrieved on: 
Tuesday, December 28, 2021
Clostridioides difficile infection, Securities Exchange Act of 1934, Annual report, Infection, Cannabinoid, Death, U.S. Securities and Exchange Commission, THC, CBDV, Gastrointestinal tract, Cramp, Ulcerative colitis, Enterococcus faecalis, Meningitis, VRE, PCT, Method, Flare, IBS, CBN, Patent Cooperation Treaty, Health, Form 10-K, GLOBE, MKT Trail, Degenerative disease, Company, MLCT, IBD, Solution, Streptococcus pneumoniae, USPTO, Risk, CBD, OTC, Irritable bowel syndrome, Drug Quality and Security Act, Behavior, Extrapyramidal system, Patent, Security (finance), Abdominal pain, Cannabidiol, Colitis, Inflammatory bowel disease, Cannabinol, Bacterial pneumonia, Securities Act of 1933, Pharmaceutical industry, Fine chemical

The Company's new patent application was filed with the USPTO and preserves our right to seek patent protection in 153 foreign nations that are signatories of the PCT.

Key Points: 
  • The Company's new patent application was filed with the USPTO and preserves our right to seek patent protection in 153 foreign nations that are signatories of the PCT.
  • Graphium Biosciences is also pursuing additional claims and patent rights through divisional applications for this patent.
  • Graphium Biosciences is also pursuing additional claims and patent rights through division applications for this patent.
  • C. diff is also a known cause of colitis, so this antimicrobial patent complements our cannabinoid glycoside patents.

Melinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™ (oritavancin)

Retrieved on: 
Monday, September 20, 2021
Biotechnology, FDA, Infectious Diseases, Health, Pharmaceutical, ACT, Therapy, OPPS, Meropenem, Clostridioides, Partial thromboplastin time, Program, MRSA, Minocycline, Staphylococcus aureus, Back pain, Bleeding, Injection, Streptococcus agalactiae, Gram, Genetically modified bacteria, PT, Diarrhea, Center for Medicare and Medicaid Innovation, Food, Regulation of tobacco by the U.S. Food and Drug Administration, MSSA, Methicillin-resistant Staphylococcus aureus, Medicare, Centers for Medicare & Medicaid Services, Adult, Itch, Streptococcus anginosus group, Drug of last resort, Glycopeptide, Elective surgery, Headache, Vomiting, Enterococcus faecalis, Patient, CMS, Limb, Nausea, INR, Warfarin, Risk, Tremor, Streptococcus pyogenes, Chest pain, ASC, Infection, Anaphylaxis, Hypersensitivity, Osteomyelitis, Prospective payment system, Center, Heparin, Chills, Pharmaceutical industry, Hospital, Sales, Vaccine

Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced two important milestones for KIMYRSA (oritavancin), a lipoglycopeptide antibiotic that was launched in July.

Key Points: 
  • Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced two important milestones for KIMYRSA (oritavancin), a lipoglycopeptide antibiotic that was launched in July.
  • We are thrilled to announce these two milestones that will expand reimbursement and access for KIMYRSA, said Christine Ann Miller, Melintas President and Chief Executive Officer.
  • Thats why we intentionally designed KIMYRSA to provide patients with more flexibility and accessibility in ABSSSI treatment.
  • Said John Harlow, Chief Commercial Officer for Melinta, Having a unique J-code for KIMYRSA underscores the distinct value that KIMYRSA brings to the oritavancin franchise.

Cystex Launches NEW Cystex Ultra Protection®, The First Clinically Shown Probiotic to Help Manage Recurrent UTIs

Retrieved on: 
Wednesday, August 18, 2021
Pain, Cranberry, Probiotic, Amazon, Urinary tract infection, Infection, Bacteria, Pharmacy, CVS, Disease, Research, Time-invariant system, OTC, Escherichia coli, Patient, Enterococcus faecalis, UTI, Tablet, Hexamethylenetetramine, FDA, Woman, Dietary supplement

Cystex Ultra Protection is the only probiotic formula clinically shown to help manage recurrent UTIs and maintain urinary tract health in over 90% of women.

Key Points: 
  • Cystex Ultra Protection is the only probiotic formula clinically shown to help manage recurrent UTIs and maintain urinary tract health in over 90% of women.
  • Seeing the unmet need for a highly effective probiotic for those sufferers, the brand developed Cystex Ultra Protection to manage and more importantly, help protect against UTIs in the future.
  • Recurrent UTIs are defined as two or more infections in six months or three or more in a year.
  • Cystex Ultra Protection is the first probiotic from the Cystex portfolio, and it accompanies Cystex Urinary Pain Relief Tablets and Cystex Urinary Health Maintenance.